Clinical Implications of Cabotegravir Plasma Levels - Charles Flexner, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

DDIs Relevant for COVID-19 Therapeutic Agents & Implementation Challenges - Fiona Marra, MPharm, MSc

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Emerging Strategies for Treating and Preventing Monkeypox 2022 - Ruth Byrne, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Long-acting Cabotegravir Pharmacokinetics With and Without Oral Lead-in for HIV PrEP - Kelong Han

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

The Non-adherent Patient A Good or Bad Candidate for CAB+RPV - Jose Castillo-Mancilla, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

CabotegravirRilpivirine Failures Despite Adherence Slides - Jose Castillo-Mancilla, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Deep Learning Ensemble Classifier to Predict Drug-Drug Interaction - Thao Pham

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Islatravir Toxicity Slides - Charles Flexner, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Lenacapavir Considerations - Jonathan Schapiro, MD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Optimization of Pharmacology Studies and DDIs in Pregnant and Lactating Individuals - Angela Colbers, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Pharmacology Pearls for Managing Absorption and Swallowing Difficulties - Saye Khoo, MD, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022

Strategies to Improve Delivery to Reservoirs as Targets for Long-Acting Antivirals - Adeniyi Olagunju, BPharm, MRes, PhD

International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2022